Table 2. Screening characteristics and outcomes of 143 FCSWs screened using concurrent hr-HPV DNA testing and EVA mobile colposcopy.
| Gross screening characteristic | Estimate |
|---|---|
| Abnormal vulval inspection findings, n (%) | 4 (2.8) |
| Abnormal vaginal inspection findings, n (%) | 3 (2.1) |
| Abnormal cervical inspection finding, n (%) | 5 (3.5) |
| TZ typeα on EVA mobile colposcopy | |
| 1 | 8 (5.6) |
| 2 | 34 (23.8) |
| 3 | 101 (70.6) |
| Screening outcome (prevalence estimates) | |
| EVA mobile colposcopy ‘positive’, % (95% CI) | 9.8 (4.9–14.7) |
| hr-HPV positive, % (95% CI) | 28.0 (20.6–35.3) |
| Single versus mixed hr-HPV infections, % (95% CI) | |
| HPV16 only | 2.1 (0.4–6.0) |
| Other hr-HPV genotypesβ | 25.2 (18.3–33.1) |
| HPV52 only | 2.1 (0.4–6.0) |
| HPV53 only | 0.7 (0.0–3.8) |
| HPV56 only | 1.4 (0.2–5.0) |
| HPV68 only | 1.4 (0.2–5.0) |
| HPV18 + HPV52 | 0.7 (0.0–3.8) |
| HPV35 + HPV45 | 0.7 (0.0–3.8) |
| HPV35 + HPV68 | 1.4 (0.2–5.0) |
| HPV35 + HPV59 | 0.7 (0.0–3.8) |
| HPV45 + HPV68 | 0.7 (0.0–3.8) |
| HPV68 + HPV52 | 2.1 (0.4–6.0) |
| HPV68 + HPV53 | 0.7 (0.0–3.8) |
| HPV58 + HPV56 | 2.1 (0.4–6.0) |
| HPV68 + HPV52 + HPV53 | 0.7 (0.0–3.8) |
| HPV68 + HPV45 + HPV53 | 0.7 (0.0–3.8) |
hr-HPV, high-risk human papillomavirus; TZ, transformation zone; CI, confidence interval; EVA, enhanced visual assessment
α
Transformation zone types
TZ1: The entire circumference of the squamocolumnar junction is visible; fully ectocervical
TZ2: The entire circumference of the squamocolumnar junction is visible; partly or fully endocervical
TZ3: The entire circumference of the squamocolumnar junction is not visible; partly or fully endocervical
β
Full genotyping (using the AmpFire platform) was completed for 26 of these 36 FCSWs identified with other hr-HPV genotypes on MA-6000 testing